AstraZeneca’s Datroway, an antibody drug conjugate (ADC), is now FDA approved for advanced cases of breast cancer that is HR positive and HER2 negative. Datroway targets TROP2, the same cancer protein addressed by Trodelvy, a Gilead Sciences ADC also approved for breast cancer.
The post AstraZeneca, Daiichi Sankyo ADC Lands FDA Approval in Advanced Breast Cancer appeared first on MedCity News.
Leave a comment